Abstract Background Subarachnoid hemorrhage (SAH) is an uncommon and serious subtype of stroke, which leads to the loss of the patient’s ability to produce and live for many years. Objective To investigate the clinical effect of nimodipine in the treatment of SAH. Methods Electronic databases including China National Knowledge Infrastructure (CNKI), VIP, SinoMed, China Master’s Theses Full-text Database (CMFD), China Doctoral Dissertations Full-text Database (CDFD), Cochrane Library, PubMed and Embase were searched from 2010 and 2021. All randomized controlled trials evaluating the efficacy of nimodipine in the treatment of SAH were included in our meta-analysis. The patients were divided into control group and treatment group. Meta-analysis was performed with Stata16.0 software. Results A total of 10 studies were included. Compared with the control group, the treatment group had higher effective rate (OR = 3.21, 95% CI: 2.25, 4.58; p < 0.001), and lower incidence of adverse reactions (OR = 0.35, 95% CI: 0.19, 0.67; p = 0.001). Before treatment, no significant differences were identified in middle cerebral artery blood flow velocity and Glasgow coma scale (GCS) score between the two groups. However, after treatment, the middle cerebral artery blood flow velocity (SMD = — 1.36, 95% CI: —2.28, —0.49; p = 0.002) and GCS score (SMD = 1.24, 95% CI: 0.58, 1.89; p < 0.001) in the treatment group were significantly better than those in the control group. Conclusions Nimodipine is effective in the treatment of SAH, lowering incidence of adverse reactions and therefore improving the prognosis of patients. (SAH stroke patient s years CNKI, CNKI , (CNKI) VIP SinoMed Masters Master Fulltext Full text CMFD, CMFD (CMFD) CDFD, CDFD (CDFD) Library 201 2021 metaanalysis. metaanalysis meta analysis. analysis meta-analysis Metaanalysis Meta Stata160 Stata Stata16 0 Stata16. software 1 OR 321 3 21 3.21 95 CI 225 2 25 2.25 4.58 458 4 58 0.001, 0001 0.001 001 035 35 0.35 019 19 0.19 0.67 067 67 0.001. . (GCS groups However SMD 136 36 1.36 2.28, 228 28 —2.28 0.49 049 49 —0.49 0.002 0002 002 124 24 1.24 058 0.58 1.89 189 89 (CNKI (CMFD (CDFD 20 202 Stata1 32 3.2 9 22 2.2 4.5 45 5 000 0.00 00 03 0.3 01 0.1 0.6 06 6 13 1.3 2.28 —2.2 0.4 04 —0.4 12 1.2 05 0.5 1.8 18 8 3. 2. 4. 0.0 0. 1. —2. —0. —2 —0

Resumo Antecedentes Hemorragia subaracnóidea (SAH) é um subtipo raro e grave de acidente vascular cerebral (AVC), o que leva à perda da capacidade do paciente de produzir e viver por muitos anos. Objetivo Investigar o efeito clínico da nimodipina no tratamento da SAH. Métodos As bases de dados eletrônicas, incluindo a China National Knowledge Infrastructure (CNKI), VIP, SinoMed, Masters Theses Full-text Database (CMFD), China Doctoral Dissertations Full-text Database (CDFD), Cochrane Library, PubMed e Embase foram pesquisadas no período de 2010 a 2021. Todos os ensaios controlados aleatorizados que avaliam a eficácia da nimodipina no tratamento da SAH foram incluídos na nossa meta-análise. Os pacientes foram divididos em grupo controle e grupo de tratamento. Meta-análise foi realizada com o software Stata 16.0. Resultados Foram incluídos um total de dez estudos. Em comparação com o grupo controle, o grupo de tratamento tinha uma taxa mais elevada (OR = 3,21, 95% CI: 2,25, 4,58; p < 0,001), e menor incidência de reações adversas (OR = 0,35, 95% CI: 0,19, 0,67; p = 0,001). Antes do tratamento, não foram identificadas diferenças significativas na velocidade média do fluxo sanguíneo da artéria cerebral e na pontuação de Glasgow coma scale (GCS) entre os dois grupos. No entanto, após o tratamento, a velocidade média do fluxo sanguíneo da artéria cerebral (SMD = −1,36, 95% CI: −2,28, 0,49; p = 0,002) e a pontuação do GCS (SMD = 1,24, 95% CI: 0,58, 1,89; p < 0,001) no grupo de tratamento foram significativamente melhores do que os do grupo controle. Conclusões A nimodipina é eficaz no tratamento da SAH, diminuindo a incidência de reações adversas e, consequentemente, melhorando o prognóstico dos doentes. (SAH AVC, AVC , (AVC) anos eletrônicas CNKI, CNKI (CNKI) VIP SinoMed Fulltext Full text CMFD, CMFD (CMFD) CDFD, CDFD (CDFD) Library 201 2021 metaanálise. metaanálise meta análise. análise meta-análise Metaanálise Meta 160 16 0 16.0 estudos OR 321 3 21 3,21 95 CI 225 2 25 2,25 4,58 458 4 58 0,001, 0001 0,001 001 035 35 0,35 019 19 0,19 0,67 067 67 0,001. . (GCS grupos entanto SMD 136 1 36 −1,36 228 28 −2,28 0,49 049 49 0,002 0002 002 124 24 1,24 058 0,58 1,89 189 89 consequentemente doentes (AVC (CNKI (CMFD (CDFD 20 202 16. 32 3,2 9 22 2,2 4,5 45 5 000 0,00 00 03 0,3 01 0,1 0,6 06 6 13 −1,3 −2,2 0,4 04 12 1,2 05 0,5 1,8 18 8 3, 2, 4, 0,0 0, −1, −2, 1, −1 −2 −

Background: Candida utilis is widely used in bioindustry, and its cell mass needs to be produced in a cost effective way. Process optimization based on the experimental results is the major way to reduce the production cost. However, this process is expensive, time consuming and labor intensive. Mathematical modeling is a useful tool for process analysis and optimization. Furthermore, sufficient information can be obtained with fewer experiments by using the mathematical modeling, and some results can be predicted even without doing experiments. Results: In the present study, we performed the mathematical modeling and simulation for the cell mass production of Candida utilis based on limited batch and repeated fedbatch experiments. The model parameters were optimized using genetic algorithm (GA), and the processes were analyzed. Conclusions: Taken together, this newly developed method is efficient, labor saving and cost effective.